Nexalin Technology (NXL) Liabilities and Shareholders Equity (2021 - 2026)
Nexalin Technology's quarterly Liabilities and Shareholders Equity came in at $3.7 million in Q1 2026, up 27.4% year-on-year from $2.9 million in Q1 2025, and down 20.29% quarter-over-quarter from $4.6 million in Q4 2025.
Nexalin Technology has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $3.7 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 27.4% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $20.0 million (up 43.58% YoY), and the FY2025 full-year result was $4.6 million, up 9.77% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $3.7 million, down from $4.6 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $8.4 million in Q3 2022, with the low at $1.6 million in Q2 2024.
- Average Liabilities and Shareholders Equity over 5 years is $4.8 million, with a median of $4.6 million recorded in 2025.
- Year-over-year, Liabilities and Shareholders Equity soared 886.09% in 2022 and plunged 69.8% in 2024.
- Tracing NXL's Liabilities and Shareholders Equity over 5 years: stood at $7.4 million in 2022, then sank by 51.13% to $3.6 million in 2023, then climbed by 16.27% to $4.2 million in 2024, then advanced by 9.77% to $4.6 million in 2025, then decreased by 20.29% to $3.7 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $3.7 million (Q1 2026), $4.6 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 91.49 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 31.92 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 6.63 Bn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 37.13 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 10.74 Bn |
| 10 | Nexalin Technology | 11.19 Mn | 8.48 Mn | 13,133.00 | 3.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.69 Mn |
| Dec 31, 2025 | 4.64 Mn |
| Sep 30, 2025 | 5.13 Mn |
| Jun 30, 2025 | 6.56 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | 4.22 Mn |
| Sep 30, 2024 | 5.26 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Dec 31, 2023 | 3.63 Mn |
| Sep 30, 2023 | 4.43 Mn |
| Jun 30, 2023 | 5.18 Mn |
| Mar 31, 2023 | 5.93 Mn |
| Dec 31, 2022 | 7.43 Mn |
| Sep 30, 2022 | 8.35 Mn |
| Dec 31, 2021 | 753,698.00 |